Aurinia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. It sells LUPKYNIS to specialty pharmacies and a specialty distributor in the United States and sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. (Otsuka), for the European and Japanese market. The Company sells encapsulated voclosporin to its collaboration partner, Otsuka, which Otsuka then sells to customers in its territories.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļAUPH
āļāļ·āđāļāļāļĢāļīāļĐāļąāļAurinia Pharmaceuticals Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJul 16, 2001
āļāļĩāļāļĩāđāļGreenleaf (Peter S)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ130
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļJul 16
āļāļĩāđāļāļĒāļđāđ#140, 14315 - 118 Avenue
āđāļĄāļ·āļāļEDMONTON
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻCanada
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđT5L 4S6
āđāļāļĢāļĻāļąāļāļāđ12507442487
āđāļ§āđāļāđāļāļāđhttps://www.auriniapharma.com
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļAUPH
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJul 16, 2001
āļāļĩāļāļĩāđāļGreenleaf (Peter S)
Mr. Peter S. Greenleaf
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Mr. Stephen P. Robertson
Chief Legal Officer, Corporate Secretary and Chief Compliance Officer
Chief Legal Officer, Corporate Secretary and Chief Compliance Officer
Mr. Ryan Cole
Chief Operating Officer
Dr. Greg Keenan
Chief Medical Officer
Ms. Jill Diane Leversage
Independent Director
Mr. Craig Johnson
Lead Independent Director
Lead Independent Director
Dr. Tina S. Nova, Ph.D.
Independent Director
Ms. Kathy L. Goetz
Independent Director
Mr. Stew Kroll
Chief Development Officer
Chief Development Officer
Mr. Thomas Wei
Chief Scientific Officer
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Mr. Peter S. Greenleaf
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Mr. Stephen P. Robertson
Chief Legal Officer, Corporate Secretary and Chief Compliance Officer
Chief Legal Officer, Corporate Secretary and Chief Compliance Officer
Mr. Ryan Cole
Chief Operating Officer
Dr. Greg Keenan
Chief Medical Officer
Ms. Jill Diane Leversage
Independent Director
Mr. Craig Johnson
Lead Independent Director
Lead Independent Director